📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Caplin Point Acquires 10 Approved ANDAs with $473.2 Million Addressable Market
Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) from a leading multinational generic company. The acquired portfolio focuses on Injectable and Ophthalmic products, which had an addressable market of $473.2 million for the 12-month period ending August 2025. This acquisition includes oncology injectables that will be manufactured at the company's new dedicated facility in Kakkalur. The company plans to commercialize these products in the U.S. and progressively expand into Mexico, Canada, the EU, and Brazil.
Key Highlights
Acquisition of 10 approved ANDAs for Injectable and Ophthalmic products from a major MNC
Addressable market for the acquired products valued at $473.2 million as of August 2025
Caplin Steriles now has 49 approvals out of 53 ANDA filings in the USA
Includes oncology injectables to be commercialized from the new dedicated Kakkalur facility
Strategic expansion planned for regulated markets including Canada, EU, and Brazil
👀 What to Watch
This acquisition is a significant positive as it provides immediate access to approved products in high-value segments, bypassing long R&D and approval cycles. Investors should monitor the commercialization timeline and the resulting revenue growth in the U.S. and other regulated markets.
Caplin Point Seeks Approval for Appointment of Vice-Chairmen and Independent Directors
Caplin Point Laboratories has initiated a postal ballot to obtain shareholder approval for several key board appointments. The company proposes appointing Mr. Ashok Partheeban and Mr. Vivek Partheeban as Directors and Vice-Chairmen to provide strategic guidance. Furthermore, Dr. K C John and Mrs. Susan Mathew are nominated as Independent Directors for five-year tenures, despite both reaching the age of 75 during their terms. The e-voting window for these resolutions is open from January 2, 2026, until January 31, 2026.
Key Highlights
Appointment of two new Vice-Chairmen, Mr. Ashok Partheeban and Mr. Vivek Partheeban, effective Nov 5, 2025
Nomination of Dr. K C John as Independent Director for a 5-year term starting November 2025
Nomination of Mrs. Susan Mathew as Independent Director for a 5-year term starting January 2026
E-voting period scheduled for 30 days from Jan 2 to Jan 31, 2026, for all eligible shareholders
👀 What to Watch
Monitor the transition in leadership as the new Vice-Chairmen take on strategic roles. Shareholders should exercise their voting rights during the January 2026 window.
Caplin Point Labs: Successful INVIMA-Colombia Inspection at Puducherry
Caplin Point Laboratories Limited announced the successful completion of an inspection by INVIMA-Colombia at its injectables facility in Puducherry. The inspection took place between December 8th and 12th, 2025. This approval is expected to facilitate the company's expansion into the Latin American market for specialty injectable products. The company already has an INVIMA approved Softgel section at the same site.
Key Highlights
INVIMA - Colombia conducted an inspection at the Puducherry injectables facility.
Inspection was conducted between December 8th and 12th, 2025.
The company has an already INVIMA approved Softgel section at the same site.
👀 What to Watch
This regulatory approval is a positive sign for Caplin Point's expansion plans; investors should monitor the company's progress in the Latin American market. Keep an eye on future announcements regarding product launches and revenue growth in the region.
Caplin Steriles gets USFDA nod for Linezolid Injection (600mg/300mL)
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA approval for Linezolid Injection, 600mg/300mL (2mg/mL) Single-dose Infusion Bags. This is a generic version of Pfizer's ZYVOX. Linezolid Injection is used to treat serious bacterial infections. The US sales for Linezolid Injection were approximately $23 million for the 12-month period ending October 2025, according to IQVIATM (IMS Health).
Key Highlights
USFDA approved Linezolid Injection 600mg/300mL (2mg/mL) Single-dose Infusion Bags for Caplin Steriles.
Linezolid Injection had US sales of approximately $23 million for the 12-month period ending October 2025.
Caplin Steriles has filed 53 ANDAs in USA with partners, with 44 approvals so far.
Caplin Steriles is working on a portfolio of 40+ simple and complex Injectable and Ophthalmic products to be filed over the next 4 years.
👀 What to Watch
This approval is a positive sign for Caplin Point, indicating successful execution in the US market. Investors should monitor the sales and market share gains of Linezolid Injection in the coming quarters.
Caplin Steriles gets USFDA approval for Acetaminophen Injection
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA approval for Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL) Single-dose Infusion Bags. This is a generic version of the Reference Listed Drug (RLD) from Mallinckrodt Pharmaceuticals Ireland Limited. Acetaminophen Injection had US sales of approximately $86 million for the 12-month period ending October 2025. Caplin Steriles has 43 ANDA approvals so far and is working on 40+ injectable and ophthalmic products.
Key Highlights
USFDA approval received for Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL)
Acetaminophen Injection had US sales of approximately $86 million (ending October 2025)
Caplin Steriles has developed and filed 53 ANDAs in USA
Caplin Steriles has 43 ANDA approvals so far
👀 What to Watch
This approval is a positive sign for Caplin Point Laboratories. Investors should monitor the sales and market share of Acetaminophen Injection in the coming quarters.
